Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Models, Statistical | 64 | 2020 | 5034 | 3.880 |
Why?
|
Causality | 24 | 2021 | 1137 | 2.980 |
Why?
|
Data Interpretation, Statistical | 32 | 2018 | 2716 | 2.810 |
Why?
|
Epidemiologic Methods | 27 | 2013 | 1346 | 2.150 |
Why?
|
Probability | 21 | 2012 | 2474 | 1.210 |
Why?
|
Epidemiologic Research Design | 5 | 2017 | 351 | 1.140 |
Why?
|
Biometry | 13 | 2010 | 542 | 1.130 |
Why?
|
Randomized Controlled Trials as Topic | 23 | 2021 | 9488 | 1.110 |
Why?
|
Estrogen Replacement Therapy | 4 | 2016 | 1178 | 1.020 |
Why?
|
Antiretroviral Therapy, Highly Active | 10 | 2015 | 1896 | 0.930 |
Why?
|
Research Design | 16 | 2021 | 5833 | 0.910 |
Why?
|
Acquired Immunodeficiency Syndrome | 11 | 2011 | 2167 | 0.900 |
Why?
|
Zidovudine | 7 | 2004 | 621 | 0.880 |
Why?
|
Braces | 1 | 2020 | 140 | 0.760 |
Why?
|
Epidemiologic Studies | 4 | 2010 | 614 | 0.760 |
Why?
|
Decompressive Craniectomy | 1 | 2020 | 83 | 0.750 |
Why?
|
Patient Dropouts | 3 | 2012 | 426 | 0.730 |
Why?
|
CD4 Lymphocyte Count | 19 | 2019 | 2543 | 0.720 |
Why?
|
Intention to Treat Analysis | 2 | 2017 | 423 | 0.710 |
Why?
|
Selection Bias | 7 | 2015 | 353 | 0.700 |
Why?
|
Anti-HIV Agents | 15 | 2019 | 4062 | 0.690 |
Why?
|
Likelihood Functions | 5 | 2018 | 989 | 0.660 |
Why?
|
Regression Analysis | 11 | 2018 | 6451 | 0.640 |
Why?
|
Sphenoid Sinus | 1 | 2017 | 101 | 0.640 |
Why?
|
Progestins | 2 | 2016 | 283 | 0.590 |
Why?
|
Craniosynostoses | 1 | 2020 | 386 | 0.580 |
Why?
|
Cerebral Palsy | 1 | 2020 | 426 | 0.570 |
Why?
|
HIV Infections | 22 | 2019 | 15538 | 0.570 |
Why?
|
Clinical Trials as Topic | 7 | 2012 | 8024 | 0.570 |
Why?
|
Bayes Theorem | 8 | 2017 | 1994 | 0.560 |
Why?
|
Computer Graphics | 2 | 2007 | 357 | 0.560 |
Why?
|
Survival Analysis | 15 | 2020 | 10507 | 0.540 |
Why?
|
Mortality | 4 | 2017 | 2732 | 0.540 |
Why?
|
Comparative Effectiveness Research | 3 | 2016 | 672 | 0.520 |
Why?
|
Endoscopy | 4 | 2022 | 1754 | 0.510 |
Why?
|
Observation | 4 | 2017 | 310 | 0.490 |
Why?
|
Pituitary Neoplasms | 2 | 2021 | 1287 | 0.490 |
Why?
|
Personnel, Hospital | 1 | 2015 | 292 | 0.480 |
Why?
|
Viral Load | 10 | 2019 | 3231 | 0.450 |
Why?
|
Disease Outbreaks | 5 | 2008 | 1709 | 0.440 |
Why?
|
Clinical Protocols | 1 | 2017 | 1470 | 0.420 |
Why?
|
Adenoma | 2 | 2021 | 2130 | 0.410 |
Why?
|
Statistics as Topic | 12 | 2016 | 2402 | 0.400 |
Why?
|
Vietnam Conflict | 1 | 2010 | 101 | 0.390 |
Why?
|
Communicable Diseases | 2 | 2008 | 797 | 0.390 |
Why?
|
Heroin Dependence | 1 | 2010 | 175 | 0.370 |
Why?
|
Computer Simulation | 13 | 2021 | 6048 | 0.370 |
Why?
|
Treatment Refusal | 4 | 2006 | 420 | 0.370 |
Why?
|
Humans | 144 | 2022 | 708843 | 0.350 |
Why?
|
Weight Gain | 3 | 2020 | 2193 | 0.340 |
Why?
|
HIV-1 | 9 | 2017 | 6757 | 0.330 |
Why?
|
Reconstructive Surgical Procedures | 1 | 2020 | 2137 | 0.310 |
Why?
|
Anti-Retroviral Agents | 3 | 2015 | 1572 | 0.310 |
Why?
|
Longitudinal Studies | 16 | 2016 | 13536 | 0.300 |
Why?
|
Cholesterol, LDL | 1 | 2016 | 2351 | 0.300 |
Why?
|
Mendelian Randomization Analysis | 1 | 2012 | 874 | 0.300 |
Why?
|
Pneumonia, Pneumocystis | 2 | 2000 | 243 | 0.280 |
Why?
|
RNA, Viral | 3 | 2019 | 2847 | 0.280 |
Why?
|
Vaccines | 2 | 2012 | 719 | 0.270 |
Why?
|
Case-Control Studies | 11 | 2004 | 21194 | 0.260 |
Why?
|
Linear Models | 3 | 2007 | 5986 | 0.240 |
Why?
|
Pharmacoepidemiology | 1 | 2006 | 291 | 0.240 |
Why?
|
Benzoxazines | 2 | 2016 | 298 | 0.240 |
Why?
|
Stroke | 3 | 2020 | 9256 | 0.230 |
Why?
|
Proportional Hazards Models | 12 | 2011 | 12292 | 0.230 |
Why?
|
Dementia | 1 | 2015 | 2227 | 0.230 |
Why?
|
Particulate Matter | 1 | 2013 | 2288 | 0.230 |
Why?
|
Mathematics | 8 | 2009 | 753 | 0.220 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2016 | 3097 | 0.220 |
Why?
|
Epidemiology | 4 | 1989 | 289 | 0.220 |
Why?
|
Drug Monitoring | 2 | 2019 | 936 | 0.220 |
Why?
|
Decision Making | 4 | 2019 | 3802 | 0.210 |
Why?
|
Citrus sinensis | 1 | 2020 | 12 | 0.210 |
Why?
|
Stochastic Processes | 5 | 2008 | 336 | 0.210 |
Why?
|
Air Pollution | 1 | 2013 | 1985 | 0.210 |
Why?
|
Malus | 1 | 2020 | 32 | 0.210 |
Why?
|
Risk | 12 | 1999 | 9641 | 0.210 |
Why?
|
Environmental Exposure | 6 | 2004 | 3954 | 0.200 |
Why?
|
Air Pollutants | 2 | 2013 | 2592 | 0.200 |
Why?
|
Smoking Cessation | 3 | 2020 | 2032 | 0.200 |
Why?
|
Rhizotomy | 1 | 2020 | 33 | 0.200 |
Why?
|
Pituitary Hormones | 1 | 2021 | 184 | 0.200 |
Why?
|
Comorbidity | 5 | 2013 | 10339 | 0.200 |
Why?
|
Multicenter Studies as Topic | 4 | 2007 | 1513 | 0.190 |
Why?
|
Visual Field Tests | 1 | 2022 | 375 | 0.190 |
Why?
|
Frontal Bone | 1 | 2020 | 105 | 0.190 |
Why?
|
Seroepidemiologic Studies | 1 | 2021 | 359 | 0.190 |
Why?
|
HIV Seropositivity | 2 | 2016 | 893 | 0.190 |
Why?
|
Quality of Life | 2 | 2020 | 11594 | 0.190 |
Why?
|
Statistics, Nonparametric | 5 | 2006 | 2945 | 0.180 |
Why?
|
Tissue Plasminogen Activator | 1 | 2005 | 1306 | 0.180 |
Why?
|
Models, Theoretical | 5 | 2017 | 3558 | 0.170 |
Why?
|
Female | 47 | 2021 | 375205 | 0.170 |
Why?
|
Therapeutic Equivalency | 1 | 1998 | 148 | 0.170 |
Why?
|
Models, Genetic | 3 | 2007 | 3539 | 0.170 |
Why?
|
Coronary Disease | 4 | 2016 | 6127 | 0.170 |
Why?
|
Educational Status | 1 | 2005 | 2278 | 0.170 |
Why?
|
Logistic Models | 6 | 2013 | 13468 | 0.160 |
Why?
|
Occupational Diseases | 7 | 1989 | 1298 | 0.160 |
Why?
|
Breast Neoplasms | 7 | 2016 | 19800 | 0.160 |
Why?
|
Genetics | 1 | 1998 | 125 | 0.160 |
Why?
|
Patient Simulation | 1 | 2020 | 307 | 0.160 |
Why?
|
Treatment Outcome | 18 | 2020 | 61932 | 0.160 |
Why?
|
Medroxyprogesterone | 1 | 2016 | 36 | 0.150 |
Why?
|
Coronary Artery Disease | 1 | 2016 | 6213 | 0.150 |
Why?
|
AIDS-Related Complex | 1 | 2016 | 110 | 0.150 |
Why?
|
Orbit | 1 | 2020 | 430 | 0.150 |
Why?
|
AIDS-Related Opportunistic Infections | 1 | 2000 | 656 | 0.150 |
Why?
|
Time Factors | 18 | 2018 | 41038 | 0.150 |
Why?
|
Ventriculoperitoneal Shunt | 1 | 2018 | 204 | 0.150 |
Why?
|
Linkage Disequilibrium | 1 | 2001 | 2062 | 0.150 |
Why?
|
Influenza, Human | 4 | 2010 | 1344 | 0.150 |
Why?
|
Learning Curve | 1 | 2017 | 202 | 0.150 |
Why?
|
Models, Biological | 4 | 2007 | 9907 | 0.150 |
Why?
|
Evaluation Studies as Topic | 2 | 2012 | 1746 | 0.150 |
Why?
|
Neoplasm, Residual | 1 | 2021 | 996 | 0.150 |
Why?
|
Fibrinolytic Agents | 1 | 2005 | 2129 | 0.140 |
Why?
|
Sarcoma, Kaposi | 1 | 1998 | 350 | 0.140 |
Why?
|
Visual Fields | 1 | 2022 | 1026 | 0.140 |
Why?
|
Education, Nursing | 1 | 2015 | 81 | 0.140 |
Why?
|
Drug Therapy, Combination | 5 | 2016 | 6562 | 0.130 |
Why?
|
Drug Administration Schedule | 5 | 2012 | 5045 | 0.130 |
Why?
|
Forced Expiratory Volume | 3 | 1992 | 1724 | 0.130 |
Why?
|
Critical Illness | 1 | 2007 | 2496 | 0.130 |
Why?
|
Bone Transplantation | 1 | 2020 | 930 | 0.130 |
Why?
|
Male | 44 | 2021 | 349524 | 0.130 |
Why?
|
Algorithms | 9 | 2010 | 13647 | 0.130 |
Why?
|
Nonlinear Dynamics | 1 | 1997 | 500 | 0.130 |
Why?
|
Ecology | 1 | 1994 | 104 | 0.130 |
Why?
|
Reverse Transcriptase Inhibitors | 2 | 2016 | 611 | 0.120 |
Why?
|
Thrombophlebitis | 1 | 1993 | 317 | 0.120 |
Why?
|
Chromosome Mapping | 1 | 2001 | 4837 | 0.120 |
Why?
|
Risk Factors | 20 | 2020 | 69553 | 0.120 |
Why?
|
Dermoid Cyst | 1 | 2013 | 94 | 0.110 |
Why?
|
Developed Countries | 4 | 2017 | 402 | 0.110 |
Why?
|
Cohort Studies | 13 | 2016 | 39292 | 0.110 |
Why?
|
Middle Aged | 32 | 2021 | 213752 | 0.110 |
Why?
|
Life Style | 3 | 2020 | 3636 | 0.110 |
Why?
|
Hydrocephalus | 1 | 2018 | 716 | 0.110 |
Why?
|
Military Personnel | 1 | 2020 | 1050 | 0.110 |
Why?
|
Cardiovascular Diseases | 4 | 2008 | 14075 | 0.110 |
Why?
|
Hospital Mortality | 1 | 2005 | 5095 | 0.110 |
Why?
|
HIV Reverse Transcriptase | 1 | 2012 | 210 | 0.110 |
Why?
|
Europe | 5 | 2017 | 3104 | 0.110 |
Why?
|
Health Status | 1 | 2005 | 4015 | 0.110 |
Why?
|
Sample Size | 2 | 2021 | 821 | 0.110 |
Why?
|
Tumor Burden | 1 | 2017 | 1906 | 0.110 |
Why?
|
Nevirapine | 1 | 2012 | 264 | 0.110 |
Why?
|
United States | 15 | 2016 | 67165 | 0.110 |
Why?
|
Cause of Death | 6 | 2017 | 3497 | 0.110 |
Why?
|
Brain Ischemia | 1 | 2005 | 3260 | 0.110 |
Why?
|
Confidence Intervals | 3 | 2010 | 2920 | 0.110 |
Why?
|
Adult | 37 | 2021 | 211041 | 0.100 |
Why?
|
Job Satisfaction | 1 | 2015 | 555 | 0.100 |
Why?
|
Postmenopause | 2 | 2016 | 2405 | 0.100 |
Why?
|
Exercise | 5 | 2020 | 5251 | 0.100 |
Why?
|
Cognition Disorders | 1 | 2005 | 3956 | 0.100 |
Why?
|
Nose Neoplasms | 1 | 2013 | 244 | 0.100 |
Why?
|
Oseltamivir | 1 | 2010 | 67 | 0.100 |
Why?
|
Fishes | 1 | 2013 | 548 | 0.100 |
Why?
|
Forecasting | 1 | 2020 | 2941 | 0.100 |
Why?
|
Scalp | 1 | 2013 | 378 | 0.100 |
Why?
|
Family Characteristics | 2 | 2012 | 924 | 0.100 |
Why?
|
Cross-Over Studies | 1 | 1995 | 2000 | 0.100 |
Why?
|
Mathematical Computing | 2 | 2007 | 147 | 0.090 |
Why?
|
Emergency Medical Services | 1 | 2020 | 1746 | 0.090 |
Why?
|
Propensity Score | 1 | 2016 | 1715 | 0.090 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2002 | 4383 | 0.090 |
Why?
|
Nose | 1 | 2013 | 488 | 0.090 |
Why?
|
Smoking | 11 | 2013 | 8612 | 0.090 |
Why?
|
Obesity | 3 | 2018 | 12031 | 0.090 |
Why?
|
Patient Compliance | 2 | 2017 | 2758 | 0.090 |
Why?
|
Epistasis, Genetic | 1 | 2010 | 374 | 0.090 |
Why?
|
Mass Screening | 1 | 2004 | 5182 | 0.080 |
Why?
|
Incidence | 5 | 2021 | 20320 | 0.080 |
Why?
|
Estrogens, Conjugated (USP) | 1 | 2008 | 254 | 0.080 |
Why?
|
Data Collection | 3 | 2001 | 3276 | 0.080 |
Why?
|
Temperature | 1 | 2013 | 2144 | 0.080 |
Why?
|
Life Expectancy | 2 | 1991 | 1116 | 0.080 |
Why?
|
Population Density | 1 | 2007 | 189 | 0.080 |
Why?
|
Random Allocation | 6 | 1990 | 2455 | 0.080 |
Why?
|
Chicago | 1 | 2007 | 245 | 0.080 |
Why?
|
Postoperative Complications | 2 | 2021 | 15053 | 0.080 |
Why?
|
Sensitivity and Specificity | 5 | 2004 | 14836 | 0.080 |
Why?
|
Mining | 1 | 1987 | 77 | 0.080 |
Why?
|
Weight Loss | 2 | 2016 | 2450 | 0.080 |
Why?
|
Heparin | 1 | 1993 | 1625 | 0.070 |
Why?
|
Influenza A Virus, H1N1 Subtype | 1 | 2010 | 461 | 0.070 |
Why?
|
Disease Transmission, Infectious | 2 | 2010 | 548 | 0.070 |
Why?
|
Odds Ratio | 5 | 2010 | 9754 | 0.070 |
Why?
|
Disease | 2 | 2004 | 694 | 0.070 |
Why?
|
Feeding Behavior | 2 | 2020 | 3141 | 0.070 |
Why?
|
Bulimia | 1 | 2007 | 395 | 0.070 |
Why?
|
Diet | 3 | 2018 | 7392 | 0.070 |
Why?
|
Urban Population | 1 | 2013 | 2006 | 0.070 |
Why?
|
Genetic Markers | 1 | 2012 | 2690 | 0.070 |
Why?
|
Prospective Studies | 11 | 2017 | 50597 | 0.070 |
Why?
|
Estrogens | 2 | 2010 | 1511 | 0.070 |
Why?
|
Double-Blind Method | 4 | 2010 | 11877 | 0.070 |
Why?
|
Reproducibility of Results | 4 | 2012 | 19423 | 0.070 |
Why?
|
Body Mass Index | 3 | 2016 | 12366 | 0.070 |
Why?
|
Follow-Up Studies | 9 | 2021 | 39038 | 0.070 |
Why?
|
Analysis of Variance | 4 | 2004 | 6530 | 0.070 |
Why?
|
Survival Rate | 4 | 2013 | 13202 | 0.070 |
Why?
|
Environment | 1 | 2010 | 1084 | 0.070 |
Why?
|
Monte Carlo Method | 3 | 2017 | 1301 | 0.060 |
Why?
|
Cyanates | 1 | 1983 | 28 | 0.060 |
Why?
|
Toluene 2,4-Diisocyanate | 1 | 1983 | 12 | 0.060 |
Why?
|
Child Development | 2 | 2006 | 2177 | 0.060 |
Why?
|
History, 20th Century | 2 | 2010 | 2837 | 0.060 |
Why?
|
Alkynes | 2 | 2016 | 320 | 0.060 |
Why?
|
Length of Stay | 1 | 2017 | 6257 | 0.060 |
Why?
|
Child | 4 | 2020 | 73636 | 0.060 |
Why?
|
Didanosine | 1 | 2003 | 157 | 0.060 |
Why?
|
Germany | 1 | 2005 | 791 | 0.060 |
Why?
|
Homosexuality, Male | 2 | 2004 | 1133 | 0.060 |
Why?
|
Markov Chains | 2 | 2017 | 991 | 0.060 |
Why?
|
Treatment Failure | 2 | 2001 | 2680 | 0.060 |
Why?
|
Cyclopropanes | 2 | 2016 | 427 | 0.060 |
Why?
|
Child, Preschool | 5 | 2020 | 41081 | 0.060 |
Why?
|
Premature Birth | 1 | 2014 | 1498 | 0.060 |
Why?
|
Atrial Fibrillation | 1 | 2020 | 4454 | 0.060 |
Why?
|
Motor Skills | 1 | 2006 | 519 | 0.060 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2021 | 8877 | 0.060 |
Why?
|
Research Subjects | 1 | 2004 | 247 | 0.060 |
Why?
|
Severe Acute Respiratory Syndrome | 1 | 2003 | 116 | 0.060 |
Why?
|
Infant | 4 | 2020 | 34261 | 0.060 |
Why?
|
Nervous System | 1 | 2006 | 563 | 0.060 |
Why?
|
Adolescent | 6 | 2020 | 84718 | 0.060 |
Why?
|
Hormone Replacement Therapy | 2 | 2013 | 732 | 0.050 |
Why?
|
Myocardial Infarction | 3 | 2005 | 11323 | 0.050 |
Why?
|
Air Pollutants, Occupational | 3 | 1989 | 367 | 0.050 |
Why?
|
Hypertension | 2 | 1998 | 8161 | 0.050 |
Why?
|
Pentamidine | 1 | 2000 | 43 | 0.050 |
Why?
|
Attitude of Health Personnel | 1 | 2015 | 3885 | 0.050 |
Why?
|
Public Health Practice | 1 | 2003 | 215 | 0.050 |
Why?
|
Databases, Factual | 1 | 2016 | 7763 | 0.050 |
Why?
|
Disease Susceptibility | 1 | 2007 | 1778 | 0.050 |
Why?
|
Carbon Compounds, Inorganic | 2 | 1989 | 10 | 0.050 |
Why?
|
Silicon Compounds | 2 | 1989 | 13 | 0.050 |
Why?
|
Risk Assessment | 4 | 2017 | 23284 | 0.050 |
Why?
|
Aged | 13 | 2021 | 161488 | 0.050 |
Why?
|
Heart | 1 | 1993 | 4315 | 0.050 |
Why?
|
Skin Neoplasms | 1 | 1998 | 5266 | 0.050 |
Why?
|
Silicon | 2 | 1989 | 132 | 0.050 |
Why?
|
Penetrance | 1 | 2000 | 359 | 0.050 |
Why?
|
Pituitary Gland | 1 | 2022 | 667 | 0.050 |
Why?
|
Prenatal Care | 1 | 2006 | 1005 | 0.040 |
Why?
|
Graft vs Leukemia Effect | 1 | 1999 | 114 | 0.040 |
Why?
|
Risperidone | 1 | 2001 | 375 | 0.040 |
Why?
|
Genetic Predisposition to Disease | 1 | 2000 | 17218 | 0.040 |
Why?
|
Medication Adherence | 1 | 2010 | 2019 | 0.040 |
Why?
|
Time | 1 | 2020 | 526 | 0.040 |
Why?
|
Infant, Newborn | 4 | 2014 | 24433 | 0.040 |
Why?
|
Infectious Disease Transmission, Vertical | 1 | 2006 | 1300 | 0.040 |
Why?
|
Boston | 2 | 2007 | 9402 | 0.040 |
Why?
|
Isoniazid | 1 | 1999 | 258 | 0.040 |
Why?
|
Health Surveys | 1 | 2008 | 3994 | 0.040 |
Why?
|
Public Health | 1 | 1991 | 2363 | 0.040 |
Why?
|
Eye | 1 | 2022 | 720 | 0.040 |
Why?
|
Models, Structural | 1 | 1998 | 380 | 0.040 |
Why?
|
Antiviral Agents | 1 | 2010 | 2768 | 0.040 |
Why?
|
Retrospective Studies | 5 | 2021 | 71483 | 0.040 |
Why?
|
Aerosols | 1 | 2000 | 689 | 0.040 |
Why?
|
Vitamins | 1 | 2006 | 1466 | 0.040 |
Why?
|
Veterans | 1 | 2010 | 2288 | 0.040 |
Why?
|
Disease Progression | 4 | 2011 | 13298 | 0.040 |
Why?
|
Developmental Disabilities | 1 | 2006 | 1370 | 0.040 |
Why?
|
Pregnancy | 4 | 2014 | 26832 | 0.040 |
Why?
|
Respiration Disorders | 2 | 1989 | 334 | 0.040 |
Why?
|
Homozygote | 1 | 2001 | 1849 | 0.040 |
Why?
|
Cluster Analysis | 1 | 2004 | 2750 | 0.040 |
Why?
|
Proteins | 1 | 2012 | 6151 | 0.040 |
Why?
|
Systems Analysis | 1 | 2017 | 166 | 0.040 |
Why?
|
Family | 1 | 2007 | 3087 | 0.040 |
Why?
|
Influenza in Birds | 2 | 2006 | 65 | 0.040 |
Why?
|
Bisexuality | 1 | 1998 | 279 | 0.040 |
Why?
|
Monitoring, Physiologic | 1 | 2004 | 1758 | 0.040 |
Why?
|
Birds | 2 | 2006 | 154 | 0.040 |
Why?
|
Carbon | 2 | 1989 | 649 | 0.040 |
Why?
|
Zimbabwe | 1 | 2015 | 108 | 0.040 |
Why?
|
Exostoses | 1 | 1975 | 32 | 0.040 |
Why?
|
Prognosis | 3 | 2021 | 28919 | 0.040 |
Why?
|
Research | 1 | 2004 | 2009 | 0.040 |
Why?
|
Equipment Failure | 1 | 2018 | 586 | 0.040 |
Why?
|
Neuropsychological Tests | 2 | 2006 | 6879 | 0.030 |
Why?
|
Influenza A Virus, H5N1 Subtype | 2 | 2006 | 113 | 0.030 |
Why?
|
Methotrexate | 1 | 2002 | 1708 | 0.030 |
Why?
|
Prevalence | 2 | 2008 | 14712 | 0.030 |
Why?
|
Disease-Free Survival | 1 | 2006 | 7026 | 0.030 |
Why?
|
Heterozygote | 1 | 2001 | 2780 | 0.030 |
Why?
|
Age Factors | 2 | 2018 | 18712 | 0.030 |
Why?
|
Benchmarking | 1 | 2020 | 915 | 0.030 |
Why?
|
Massachusetts | 2 | 2016 | 8712 | 0.030 |
Why?
|
Spondylitis, Ankylosing | 1 | 1975 | 143 | 0.030 |
Why?
|
Peripheral Nervous System Diseases | 1 | 1999 | 697 | 0.030 |
Why?
|
Pregnancy Complications, Infectious | 1 | 2006 | 1999 | 0.030 |
Why?
|
HIV Protease Inhibitors | 1 | 2016 | 435 | 0.030 |
Why?
|
Anti-Infective Agents | 1 | 2000 | 927 | 0.030 |
Why?
|
Gene Frequency | 1 | 2000 | 3701 | 0.030 |
Why?
|
Developing Countries | 1 | 2006 | 2674 | 0.030 |
Why?
|
Phenotype | 2 | 2001 | 16306 | 0.030 |
Why?
|
Dietary Supplements | 1 | 2006 | 3025 | 0.030 |
Why?
|
Antidepressive Agents | 1 | 2005 | 2813 | 0.030 |
Why?
|
Mammography | 1 | 2004 | 2442 | 0.030 |
Why?
|
Neoplasms, Radiation-Induced | 1 | 1997 | 565 | 0.030 |
Why?
|
Birth Weight | 2 | 1999 | 1893 | 0.030 |
Why?
|
Injections, Subcutaneous | 1 | 1993 | 685 | 0.030 |
Why?
|
Antirheumatic Agents | 1 | 2002 | 1347 | 0.030 |
Why?
|
Mental Disorders | 1 | 2012 | 6395 | 0.030 |
Why?
|
El Salvador | 1 | 1991 | 41 | 0.030 |
Why?
|
Tanzania | 2 | 2006 | 1168 | 0.030 |
Why?
|
Lung Neoplasms | 3 | 1998 | 12183 | 0.030 |
Why?
|
Endometrial Neoplasms | 1 | 2001 | 1333 | 0.030 |
Why?
|
Toxoplasmosis | 1 | 1991 | 89 | 0.030 |
Why?
|
Uganda | 1 | 2015 | 1097 | 0.030 |
Why?
|
Wisconsin | 1 | 2010 | 126 | 0.030 |
Why?
|
Bone Marrow Transplantation | 1 | 1999 | 2789 | 0.020 |
Why?
|
Bipolar Disorder | 1 | 2007 | 5023 | 0.020 |
Why?
|
Medroxyprogesterone Acetate | 1 | 2010 | 148 | 0.020 |
Why?
|
Young Adult | 4 | 2021 | 55940 | 0.020 |
Why?
|
Asbestos | 1 | 1991 | 188 | 0.020 |
Why?
|
Sulfur Dioxide | 1 | 1989 | 147 | 0.020 |
Why?
|
Registries | 1 | 2005 | 7989 | 0.020 |
Why?
|
Leukemia, Radiation-Induced | 1 | 1988 | 43 | 0.020 |
Why?
|
Neoplasms, Second Primary | 1 | 1997 | 985 | 0.020 |
Why?
|
Alleles | 1 | 2000 | 7090 | 0.020 |
Why?
|
Polymorphism, Genetic | 1 | 1999 | 4293 | 0.020 |
Why?
|
Alcohol Drinking | 2 | 2013 | 3713 | 0.020 |
Why?
|
Infusions, Intravenous | 1 | 1993 | 2303 | 0.020 |
Why?
|
Rwanda | 1 | 2011 | 746 | 0.020 |
Why?
|
Sampling Studies | 1 | 1989 | 639 | 0.020 |
Why?
|
Meta-Analysis as Topic | 1 | 1993 | 1336 | 0.020 |
Why?
|
Accidents, Home | 1 | 1988 | 70 | 0.020 |
Why?
|
Chemoprevention | 1 | 2010 | 313 | 0.020 |
Why?
|
Aged, 80 and over | 3 | 2021 | 58184 | 0.020 |
Why?
|
Depressive Disorder | 1 | 2000 | 3811 | 0.020 |
Why?
|
Cooperative Behavior | 1 | 2015 | 1551 | 0.020 |
Why?
|
Silicosis | 1 | 1986 | 42 | 0.020 |
Why?
|
Hyperlipidemias | 1 | 1992 | 796 | 0.020 |
Why?
|
Psychotic Disorders | 1 | 2001 | 2800 | 0.020 |
Why?
|
Containment of Biohazards | 1 | 2006 | 38 | 0.020 |
Why?
|
Arthritis, Rheumatoid | 1 | 2002 | 3609 | 0.020 |
Why?
|
Eating | 1 | 2013 | 1443 | 0.020 |
Why?
|
Depression | 1 | 2005 | 7202 | 0.020 |
Why?
|
Antipsychotic Agents | 2 | 2015 | 3033 | 0.020 |
Why?
|
Animals | 5 | 2013 | 170486 | 0.020 |
Why?
|
Maximal Expiratory Flow Rate | 1 | 1984 | 42 | 0.020 |
Why?
|
Ethics, Medical | 1 | 1991 | 803 | 0.020 |
Why?
|
Forced Expiratory Flow Rates | 1 | 1984 | 75 | 0.020 |
Why?
|
Family Health | 1 | 2010 | 1276 | 0.020 |
Why?
|
Anticoagulants | 1 | 2020 | 4293 | 0.020 |
Why?
|
Accidents, Traffic | 1 | 1991 | 794 | 0.020 |
Why?
|
Health Promotion | 1 | 2017 | 2172 | 0.020 |
Why?
|
Respiratory Function Tests | 2 | 1986 | 1673 | 0.020 |
Why?
|
Overweight | 1 | 2016 | 2205 | 0.020 |
Why?
|
Prenatal Exposure Delayed Effects | 1 | 1996 | 2290 | 0.020 |
Why?
|
Maximum Allowable Concentration | 1 | 1983 | 59 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2016 | 11239 | 0.020 |
Why?
|
Hong Kong | 1 | 2003 | 156 | 0.020 |
Why?
|
Genotype | 1 | 1998 | 12863 | 0.010 |
Why?
|
Patient Isolation | 1 | 2003 | 106 | 0.010 |
Why?
|
Morbidity | 1 | 1988 | 1690 | 0.010 |
Why?
|
Cities | 1 | 2004 | 493 | 0.010 |
Why?
|
Singapore | 1 | 2003 | 305 | 0.010 |
Why?
|
Communicable Disease Control | 2 | 2004 | 811 | 0.010 |
Why?
|
Multivariate Analysis | 2 | 1996 | 12447 | 0.010 |
Why?
|
Pilot Projects | 1 | 2015 | 7994 | 0.010 |
Why?
|
Spirometry | 1 | 1984 | 866 | 0.010 |
Why?
|
Lead Poisoning | 1 | 1983 | 287 | 0.010 |
Why?
|
Quarantine | 1 | 2003 | 163 | 0.010 |
Why?
|
Longevity | 1 | 1988 | 1019 | 0.010 |
Why?
|
Contact Tracing | 1 | 2003 | 258 | 0.010 |
Why?
|
Malaria | 1 | 1990 | 1076 | 0.010 |
Why?
|
Disaster Planning | 1 | 2006 | 535 | 0.010 |
Why?
|
Tuberculosis | 1 | 2011 | 1769 | 0.010 |
Why?
|
Kaplan-Meier Estimate | 1 | 2010 | 6765 | 0.010 |
Why?
|
Lung | 2 | 1989 | 9706 | 0.010 |
Why?
|
Lead | 1 | 1983 | 798 | 0.010 |
Why?
|
Diagnostic Errors | 1 | 1985 | 1260 | 0.010 |
Why?
|
Physicians | 1 | 2015 | 4292 | 0.010 |
Why?
|
Psychomotor Performance | 1 | 2006 | 1938 | 0.010 |
Why?
|
Health Behavior | 1 | 2009 | 2576 | 0.010 |
Why?
|
Diabetes Mellitus | 1 | 2015 | 5348 | 0.010 |
Why?
|
Burns | 1 | 1988 | 1788 | 0.010 |
Why?
|
Placebos | 1 | 2001 | 1733 | 0.010 |
Why?
|
Heel | 1 | 1975 | 36 | 0.010 |
Why?
|
Elbow | 1 | 1975 | 147 | 0.010 |
Why?
|
Knee | 1 | 1975 | 243 | 0.010 |
Why?
|
Wrist | 1 | 1975 | 207 | 0.010 |
Why?
|
Health Policy | 1 | 2006 | 2615 | 0.010 |
Why?
|
Humerus | 1 | 1975 | 251 | 0.010 |
Why?
|
RNA | 1 | 2003 | 2680 | 0.010 |
Why?
|
Pelvic Bones | 1 | 1975 | 271 | 0.010 |
Why?
|
Forearm | 1 | 1975 | 406 | 0.010 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2016 | 10857 | 0.010 |
Why?
|
Infant, Low Birth Weight | 1 | 1996 | 833 | 0.010 |
Why?
|
Occupations | 2 | 1984 | 469 | 0.010 |
Why?
|
Foot | 1 | 1975 | 506 | 0.010 |
Why?
|
Leukemia | 1 | 1999 | 1496 | 0.010 |
Why?
|
Thoracic Vertebrae | 1 | 1975 | 613 | 0.010 |
Why?
|
Hand | 1 | 1975 | 860 | 0.010 |
Why?
|
Leg | 1 | 1975 | 1160 | 0.010 |
Why?
|
Aging | 2 | 1986 | 8358 | 0.010 |
Why?
|
Age of Onset | 1 | 1996 | 3330 | 0.010 |
Why?
|
Syndrome | 1 | 1975 | 3177 | 0.010 |
Why?
|
Immunization Schedule | 1 | 1990 | 216 | 0.010 |
Why?
|
Femur | 1 | 1975 | 1274 | 0.010 |
Why?
|
Cervical Vertebrae | 1 | 1975 | 958 | 0.010 |
Why?
|
Immunization, Secondary | 1 | 1990 | 341 | 0.010 |
Why?
|
Vital Capacity | 1 | 1989 | 910 | 0.000 |
Why?
|
Dust | 1 | 1989 | 462 | 0.000 |
Why?
|
National Health Programs | 1 | 1990 | 438 | 0.000 |
Why?
|
Brazil | 1 | 1990 | 1129 | 0.000 |
Why?
|
Lumbar Vertebrae | 1 | 1975 | 1817 | 0.000 |
Why?
|
Radiography | 1 | 1975 | 6989 | 0.000 |
Why?
|
Immunity | 1 | 1990 | 957 | 0.000 |
Why?
|
Edetic Acid | 1 | 1983 | 283 | 0.000 |
Why?
|
Connecticut | 1 | 1983 | 363 | 0.000 |
Why?
|
Employment | 1 | 1989 | 1087 | 0.000 |
Why?
|
Blood Cell Count | 1 | 1983 | 422 | 0.000 |
Why?
|
Hematocrit | 1 | 1983 | 636 | 0.000 |
Why?
|
Hemolysis | 1 | 1983 | 407 | 0.000 |
Why?
|
Program Evaluation | 1 | 1990 | 2524 | 0.000 |
Why?
|
Anemia | 1 | 1983 | 1403 | 0.000 |
Why?
|
Chronic Disease | 1 | 1983 | 8992 | 0.000 |
Why?
|
Cross-Sectional Studies | 1 | 1986 | 23020 | 0.000 |
Why?
|
Neoplasms | 1 | 1985 | 20172 | 0.000 |
Why?
|